Cannara Biotech (8CB0) Financial Statements
0 Followers
Cannara Biotech Financial Overview
Cannara Biotech's market cap is currently $127.09M. The company's EPS TTM is $0.11; its P/E ratio is 18.40; Cannara Biotech is estimated to report earnings on November 24, 2026, and the estimated EPS forecast is $0.02. See an overview of income statement, balance sheet, and cash flow financials.
| Aug 25 | Aug 24 | Nov 23 | Aug 22 | Nov 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 107.32M | $ 81.75M | $ 57.26M | $ 35.84M | $ 17.02M |
| Gross Profit | $ 47.22M | $ 29.79M | $ 27.23M | $ 16.74M | $ 11.86M |
| Operating Income | $ 22.20M | $ 10.08M | $ 11.89M | $ 4.39M | $ 1.82M |
| EBITDA | $ 28.46M | $ 15.16M | $ 15.77M | $ 7.85M | $ 4.63M |
| Net Income | $ 13.08M | $ 6.44M | $ 6.95M | $ 2.31M | $ -1.53M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 14.36M | $ 6.62M | $ 4.27M | $ 12.11M | $ 8.16M |
| Total Assets | $ 168.65M | $ 154.72M | $ 141.52M | $ 125.62M | $ 92.02M |
| Total Debt | $ 41.58M | $ 48.33M | $ 45.78M | $ 48.39M | $ 20.90M |
| Net Debt | $ 27.22M | $ 41.71M | $ 41.51M | $ 36.28M | $ 12.74M |
| Total Liabilities | $ 66.43M | $ 66.77M | $ 61.78M | $ 58.88M | $ 27.91M |
| Stockholders' Equity | $ 102.22M | $ 87.95M | $ 79.74M | $ 66.74M | $ 64.12M |
| Cash Flow | |||||
| Free Cash Flow | $ 13.65M | $ 3.21M | $ -3.97M | $ -21.55M | $ -33.17M |
| Operating Cash Flow | $ 20.01M | $ 10.68M | $ 5.91M | $ -6.08M | $ -2.09M |
| Investing Cash Flow | $ -5.95M | $ -5.19M | $ -9.48M | $ -15.35M | $ -30.83M |
| Financing Cash Flow | $ -6.32M | $ -3.14M | $ -4.19M | $ 25.46M | $ 33.25M |
Currency in CAD
